Silvercrest Asset Management Group LLC Halozyme Therapeutics, Inc. Transaction History
Silvercrest Asset Management Group LLC
- $14.3 Billion
- Q3 2024
A detailed history of Silvercrest Asset Management Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Silvercrest Asset Management Group LLC holds 636,589 shares of HALO stock, worth $30.3 Million. This represents 0.25% of its overall portfolio holdings.
Number of Shares
636,589
Previous 603,631
5.46%
Holding current value
$30.3 Million
Previous $31.6 Million
15.23%
% of portfolio
0.25%
Previous 0.23%
Shares
17 transactions
Others Institutions Holding HALO
# of Institutions
543Shares Held
125MCall Options Held
294KPut Options Held
180K-
Black Rock Inc. New York, NY17.6MShares$838 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.9MShares$613 Million0.01% of portfolio
-
State Street Corp Boston, MA6.63MShares$315 Million0.02% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.06MShares$193 Million5.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.41MShares$162 Million0.07% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $6.62B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...